» Articles » PMID: 25237832

Transcriptional Profiling of GBM Invasion Genes Identifies Effective Inhibitors of the LIM Kinase-Cofilin Pathway

Overview
Journal Oncotarget
Specialty Oncology
Date 2014 Sep 20
PMID 25237832
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Malignant gliomas are highly proliferative and invasive neoplasms where total surgical resection is often impossible and effective local radiation therapy difficult. Consequently, there is a need to develop a greater understanding of the molecular events driving invasion and to identify novel treatment targets. Using microarray analysis comparing normal brain samples and mesenchymal glioblastoma multiforme (GBM), we identified over 140 significant genes involved in cell migration and invasion. The cofilin (CFL) pathway, which disassembles actin filaments, was highly up-regulated compared to normal brain. Up-regulation of LIM domain kinase 1 and 2 (LIMK1/2), that phosphorylates and inactivates cofilin, was confirmed in an additional independent data set comparing normal brain to GBM. We identified and utilized two small molecule inhibitors BMS-5 and Cucurbitacin I directed against the cofilin regulating kinases, LIMK1 and LIMK2, to target this pathway. Significant decreases in cell viability were observed in glioma cells treated with BMS-5 and Cucurbitacin I, while no cytotoxic effects were seen in normal astrocytes that lack LIMK. BMS-5 and Cucurbitacin I promoted increased adhesion in GBM cells, and decreased migration and invasion. Collectively, these data suggest that use of LIMK inhibitors may provide a novel way to target the invasive machinery in GBM.

Citing Articles

Biphasic regulation of epigenetic state by matrix stiffness during cell reprogramming.

Song Y, Soto J, Wong S, Wu Y, Hoffman T, Akhtar N Sci Adv. 2024; 10(7):eadk0639.

PMID: 38354231 PMC: 10866547. DOI: 10.1126/sciadv.adk0639.


LIM Kinases, LIMK1 and LIMK2, Are Crucial Node Actors of the Cell Fate: Molecular to Pathological Features.

Villalonga E, Mosrin C, Normand T, Girardin C, Serrano A, Zunar B Cells. 2023; 12(5).

PMID: 36899941 PMC: 10000741. DOI: 10.3390/cells12050805.


Cofilin Acts as a Booster for Progression of Malignant Tumors Represented by Glioma.

Lv S, Chen Z, Mi H, Yu X Cancer Manag Res. 2022; 14:3245-3269.

PMID: 36452435 PMC: 9703913. DOI: 10.2147/CMAR.S389825.


Modulation of Cytoskeleton, Protein Trafficking, and Signaling Pathways by Metabolites from , and Plant Families.

Patel A, Rasheed A, Reilly I, Pareek Z, Hansen M, Haque Z Pharmaceuticals (Basel). 2022; 15(11).

PMID: 36355554 PMC: 9698530. DOI: 10.3390/ph15111380.


The microtubule cytoskeleton: An old validated target for novel therapeutic drugs.

Lafanechere L Front Pharmacol. 2022; 13:969183.

PMID: 36188585 PMC: 9521402. DOI: 10.3389/fphar.2022.969183.


References
1.
Manetti F . LIM kinases are attractive targets with many macromolecular partners and only a few small molecule regulators. Med Res Rev. 2012; 32(5):968-98. DOI: 10.1002/med.20230. View

2.
Sarmiere P, Bamburg J . Head, neck, and spines: a role for LIMK-1 in the hippocampus. Neuron. 2002; 35(1):3-5. DOI: 10.1016/s0896-6273(02)00759-6. View

3.
Ross-Macdonald P, de Silva H, Guo Q, Xiao H, Hung C, Penhallow B . Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors. Mol Cancer Ther. 2008; 7(11):3490-8. DOI: 10.1158/1535-7163.MCT-08-0826. View

4.
Salhia B, Tran N, Symons M, Winkles J, Rutka J, Berens M . Molecular pathways triggering glioma cell invasion. Expert Rev Mol Diagn. 2006; 6(4):613-26. DOI: 10.1586/14737159.6.4.613. View

5.
Davila M, Frost A, Grizzle W, Chakrabarti R . LIM kinase 1 is essential for the invasive growth of prostate epithelial cells: implications in prostate cancer. J Biol Chem. 2003; 278(38):36868-75. DOI: 10.1074/jbc.M306196200. View